While our study suggests similar clinical effects of PD-1 plus chemotherapy and PD-L1 plus chemotherapy, caution is warranted in utilizing PD-1 plus chemotherapy as first-line treatment for ES-SCLC [24]. Here, CD274 is linked to small cell lung carcinoma.